SCIENTIFIC REPORTS

Received: 10 August 2016 Accepted: 25 November 2016 Published: 24 January 2017

OPEN Functional PTGS2 polymorphismbased models as novel predictive markers in metastatic renal cell carcinoma patients receiving firstline sunitinib

Arancha Cebrián^{1,*}, Teresa Gómez del Pulgar^{1,*}, María José Méndez-Vidal², María Luisa Gonzálvez³, Nuria Lainez⁴, Daniel Castellano⁵, Iciar García-Carbonero⁶, Emilio Esteban⁷, Maria Isabel Sáez⁸, Rosa Villatoro⁹, Cristina Suárez¹⁰, Alfredo Carrato¹¹, Javier Munárriz-Ferrándiz¹², Laura Basterrechea¹³, Mirta García-Alonso¹⁴, José Luis González-Larriba¹⁵, Begoña Perez-Valderrama¹⁶, Josefina Cruz-Jurado¹⁷, Aránzazu González del Alba¹⁸, Fernando Moreno¹⁹, Gaspar Reynés²⁰, María Rodríguez-Remírez¹, Valentina Boni²¹, Ignacio Mahillo-Fernández¹, Yolanda Martin²², Andrea Viqueira²³ & Jesús García-Foncillas¹

Sunitinib is the currently standard treatment for metastatic renal cell carcinoma (mRCC). Multiple candidate predictive biomarkers for sunitinib response have been evaluated but none of them has been implemented in the clinic yet. The aim of this study was to analyze single nucleotide polymorphisms (SNPs) in genes linked to mode of action of sunitinib and immune response as biomarkers for mRCC. This is a multicenter, prospective and observational study involving 20 hospitals. Seventy-five mRCC patients treated with sunitinib as first line were used to assess the impact of 63 SNPs in 31 candidate genes on clinical outcome. rs2243250 (IL4) and rs5275 (PTGS2) were found to be significantly associated with shorter cancer-specific survival (CSS). Moreover, allele C (rs5275) was associated with higher PTGS2 expression level confirming its functional role. Combination of rs5275 and rs7651265 or rs2243250 for progression free survival (PFS) or CSS, respectively, was a more valuable predictive biomarker remaining significant after correction for multiple testing. It is the first time that association of rs5275 with survival in mRCC patients is described. Two-SNP models containing this functional variant may serve as more predictive biomarkers for sunitinib and could suppose a clinically relevant tool to improve the mRCC patient management.

Renal cell carcinoma (RCC) is the most common type of kidney cancer worldwide¹. Approximately 25% of patients will have metastatic disease at presentation² and, despite an attempted curative surgery, around 20-30% of patients will recur¹. Over the last years, the clarification of molecular mechanisms has transformed its management.

¹Fundación Jiménez Díaz University Hospital, Madrid, Spain. ²Reina Sofía University Hospital, Córdoba, Spain. ³Virgen de la Arrixaca University Hospital, Murcia, Spain. ⁴Complejo Hospitalario de Navarra, Pamplona, Spain. ⁵12 de Octubre University Hospital, Madrid, Spain. ⁶Virgen de la Salud University Hospital, Toledo, Spain. ⁷Central University Hospital of Asturias, Oviedo, Spain. ⁸Virgen de la Victoria University Hospital, Málaga, Spain. ⁹Hospital Costa del Sol, Marbella, Spain. ¹⁰Vall d'Hebron University Hospital, Barcelona, Spain. ¹¹Ramon y Cajal University Hospital, Madrid, Spain. ¹²Hospital Provincial de Castellón, Castellón, Spain. ¹³Hospital de Donostia, San Sebastian, Spain. ¹⁴Insular de Gran Canaria University Hospital, Islas Canarias, Spain. ¹⁵Clinico San Carlos University Hospital, Madrid, Spain. ¹⁶Virgen del Rocío University Hospital, Sevilla, Spain. ¹⁷Canarias University Hospital, Santa Cruz de Tenerife, Islas Canarias, Spain. ¹⁸Son Espases University Hospital, Palma de Mallorca, Spain. ¹⁹Fuenlabrada University Hospital, Fuenlabrada, Spain. ²⁰La Fe University Hospital, Valencia, Spain. ²¹Center for Applied Medical Research, Pamplona, Spain. ²²Trial Form Support, Madrid, Spain. ²³Pfizer Oncology, Madrid, Spain. *These authors contributed equally to this work. Correspondence and requests for materials should be addressed to J.G.F. (email: jesus.garciafoncillas@oncohealth.eu)

Sunitinib is the gold standard drug for the treatment of metastatic RCC (mRCC) as first- and second-line therapy. It is a tyrosine kinase receptor inhibitor affecting angiogenesis pathway since it blocks VEGF receptors-1,– 2,–3 as well as platelet-derived growth factor receptors (PDGFR- α and $-\beta$), FLT-3, RET and c-Kit³. Although 50% of RCC patients treated with sunitinib show an objective response and 43% reach disease stabilization, 7% will suffer progressive disease at first evaluation⁴. The identification of biomarkers able to predict sunitinib sensitivity/resistance could avoid unnecessary costs and side effects, guiding alternative treatment decisions.

The mammalian target of rapamycin (mTOR) pathway plays a key role in cell growth regulation and angiogenesis and, it is activated downstream by activation of tyrosine kinase receptors, such as VEGFR through phosphoinositide 3-kinase (PI3K)/Akt pathway. It has been recently described that sunitinib completely abrogates PI3K/ AKT/mTOR survival signaling⁵.

One of the hallmarks of cancer is the inflammatory microenvironment⁶. Recently, it has been correlated the persistence of chronic inflammation and reduced survival in advanced RCC patients^{7,8}. A wide variety of proand anti-inflammatory mediators regulate immune response, among them interleukin-1 β (IL-1 β) and tumor necrosis factor- α (TNF- α) are potent pro-inflammatory cytokines involved in both cancer development and progression. On the contrary, IL-4, IL-10 and tumor growth factor- β (TGF- β) are effective negative regulators of the immune response, and they have been involved at different levels in RCC disease such as cellular senescence⁹ and increased incidence of metastasis^{10,11}.

In addition to cytokines and growth factors, cyclooxygenase 2 (COX-2) has been implicated in carcinogenesis and metastatic progression of different types of cancers including RCC¹². COX-2 expression significantly correlates with increased microvessel density, higher stage and grade^{13,14}. The gene which encodes COX-2 (*PTGS2*) is induced in response to cytokines, and other inflammatory and mitogenic stimuli.

Patient genetic background could play an important role especially with regard to the drugs that interact with the tumor microenvironment and non-malignant endothelial cells such as sunitinib. Genes involved in the pathways mentioned above harbor polymorphic variants that have been associated with the outcome in different cancers. However, little is known about their roles in mRCC, except for some located in angiogenesis-related genes. Trying to address this issue, we aimed to assess the predictive role of 63 single nucleotide polymorphisms (SNPs) in genes that affect the mode of action of sunitinib and inflammatory response.

Results

A total of 75 mRCC patients receiving first-line sunitinib treatment was studied (Table 1). Median age at diagnosis was 63 years (range 26–87). According to the MSKCC prognostic criteria, patients were categorized into favourable (2%), intermediate (68%) and poor (23%) groups. At the time of analysis, 45 out of 75 patients (60%) had disease progression and 27 (36%) had died. The median follow up of the 75 patients was 12.2 months (range 1–28).

Association of Genetic variants with Outcome. The genotypes and allele frequencies for each polymorphism are given in Table 2. The association of individual SNPs with PFS and CSS was assessed by Cox regression analysis under codominant, dominant, recessive and additive models and the best model was chosen (Supplementary Table S1). All those meeting a P < 0.1 were selected as candidate for multivariate Cox regression analysis (Table 3). Clinical and biochemical parameters associated with PFS and CSS were also assessed (Supplementary Table S2). To analyze the effect of SNPs on PFS and CSS, both the MSKCC score and prior nephrectomy were considered as covariates whereas histology was only considered for CSS.

Multivariate analyses showed that PFS was significantly associated with SNPs rs7651265 in *PIK3CA* and rs307826 in *FLT4* (Table 3). Cancer-specific survival was significantly associated with SNPs rs2243250 in *IL4* and rs5275 in *PTGS2*, both of them remained significant after correction for multiple testing using the Benjamini-Hochberg method (Table 3).

Specifically, the CT and TT genotypes for rs2243250 showed inferior median CSS compared with the wild-type CC genotype (13.1 months *vs.* not reached; HR, 4.69; 95% CI, 1.92–11.44; P = 0.0009; Table 3 and Fig. 1A). This SNP is located in the *IL4* promoter region and its functionality has been previously described^{15,16}. Our result is in accordance with the prognostic value of this variant in immunotherapy-treated mRCC patients¹⁷.

Regarding to rs5275 in *PTGS2*, a total of 67 patients had TT/TC genotypes, whereas 7 patients were CC. Median CSS was not reached for TT/TC patients, and was only 8.9 months for rare homozygous patients (HR, 5.22; 95% CI, 1.70–15.98; P = 0.01; Table 3 and Fig. 1B). As this SNP is located in the 3' untranslated region (3'UTR) of *PTGS2* mRNA and disrupts microRNA-mediated regulation¹⁸, *PTGS2* mRNA expression levels were compared between the two groups of patients (TT/TC vs CC). We confirmed that CC patients showed higher levels of *PTGS2* expression than TT/TC patients (Fig. 1C).

Predictive two-SNPs models for outcome. Among the significant SNPs after multivariate adjustment for PFS or CSS (Table 3), we tested different combinations in order to find models with higher predictive value than the single predictors. To assess and compare the predictive ability of the individual variants and the two-SNPs models, the AUC was determined.

Three different combinations were tested for PFS (rs307826 and rs7651265; rs5275 and rs7651265; rs307826 and rs5275). We found that the combination of deleterious genotypes for rs5275 (CC) in *PTGS2* and rs7651265 (AA) in *PIK3CA* was strongly associated with lower PFS (P=0.001; Fig. 2A). As shown in Table 4, patients with both deleterious genotypes were almost 5.5 times more likely to progress compared to those without these genotypes (HR, 5.44; 95% CI, 1.39–21.32; P=0.015). The predictive capacity of this model was better than the individual SNPs since its AUC was 0.702 compared to 0.595 (rs5275) and 0.671 (rs7651265) (Supplementary Table S3). This combination was the best predictor to discriminate the three risk groups compared to the other two combinations (rs307826 and rs7651265; rs307826 and rs5275) (Supplementary Table S4). Regarding to CSS, three risk groups were identified according to the deleterious genotypes combination of polymorphisms rs5275 (CC) in

	Patients (n = 75)
Age	
Median, y	63
Range	26-87
Gender	
Male	50 (67%)
Female	25 (33%)
Histology	
Clear cell	56 (75%)
Other	13 (17%)
Undetermined	6 (8%)
Prior nephrectomy	
No	16 (21%)
Yes	59 (79%)
Fuhrman grade	
G1-G2	14 (19%)
G3-G4	32 (42%)
Undetermined	29 (39%)
ECOG performance status	
0	28 (37%)
1	38 (51%)
2	9 (12%)
Number of metastatic sites	
<2	33 (44%)
>2	42 (56%)
Platelets	
< 400000	61 (81%)
> 400000	13 (17%)
Undetermined	1 (1%)
MSKCC score	
Favourable	2 (2%)
Intermediate	51 (68%)
Poor	17 (23%)
Undetermined	5 (7%)

 Table 1. Patient characteristics. Abbreviations: ECOG, Eastern Cooperative Oncology Group; MSKCC, Memorial Sloan-Kettering Cancer Center.

PTGS2 and rs2243250 (CT/TT) in *IL4* (P=0.008; Fig. 2B). This two-SNPs model was strongly associated with a higher risk of death (HR, 7.32; 95% CI, 2.10–25.54; P=0.002; Table 4) and showed higher ability to predict CSS (AUC=0.671) than each SNP separately (AUC=0.649) (Supplementary Table S3).

Both combination of *PTGS2* & *PIK3CA* for PFS and combination of *PTGS2* & *IL4* for CSS remained significant after multiple testing correction.

Discussion

A set of polymorphisms located in genes involved in the mode of action of sunitinib and in the immune response were assessed as potential markers of mRCC outcome.

IL-4 is a pleiotropic cytokine which mediates a variety of interactions among components of the immune system. High levels of IL-4 in the tumour microenvironment have been correlated with the grade of malignancy and tumor resistance to apoptosis¹⁹. The functional genetic variant, rs2243250, located at the promoter region, drives more than 3-fold greater *IL4* expression when T allele is present since allele T showed greater binding to nuclear transcription factors than allele C¹⁵. Nakashima *et al.* assessed the functional consequences of this SNP *in vivo* and found that the mean percentages of peripheral Th cells for patients with genotype CC was significantly lower than those with allele T (TT/TC)¹⁶. Little is known about the role of this variant in cancer since few studies have analyzed this SNP in the context of cancer risk and, only a single-center study in immunotherapy-treated mRCC patients has described it as genetic prognostic factor¹⁷. In this study, we show the significant association of rs2243250 with the sunitinib response since mRCC patients with T-allele have shorter cancer-specific survival. The fact that significance between genotypes with or without T allele has been observed in the proportion of Th cells producing IL4¹⁶ makes it likely that IL4 genotype could influence the type of immune response. Therefore, it might be related to the prevention of effective immune surveillance by TH1 cells during disease progression¹⁷.

Moreover, we demonstrate clearly, for the first time, the predictive role of the functional SNP rs5275 in *PTGS2* gene in mRCC patients. T-allele conferred a significant survival advantage since the rare homozygous variant

Gene	SNP	Variation	Patients*	Homozygous wild-type	Heterozygous	Homozygous variant	Observed MAF	MAF in dbSNP
AKT1	rs3803304 C>G	Intron	75	41	28	6	0.27	0.22
AKT1	rs2498804 G > T	3'near gene	75	31	35	9	0.35	0.34
AKT1	rs2494738 G > A	Intron	71	57	13	1	0.11	0.07
AKT1	rs1130214 G>T	5'-UTR	75	41	31	3	0.25	0.28
AKT2	rs8100018 G>C	Intron	75	43	29	3	0.23	0.26
AKT2	rs892119 G > A	Intron	75	55	19	1	0.14	0.14
AKT3	rs12045585 G > A	Intron	75	54	20	1	0.15	0.13
AKT3	rs2994329 G > A	Intron	74	46	27	1	0.20	0.20
ARNT	rs2228099 C>G	V189V	73	24	41	8	0.39	0.39
CXCL12	rs1801157 G>A	3'-UTR	73	41	32	0	0.22	0.21
FGFR2	rs2981582 C>T	Intron	75	32	24	19	0.41	0.46
FGFR4	rs351855 C>T	G388R	73	34	33	6	0.31	0.28
FLT3	rs1933437 T>C	T227M	73	21	40	12	0.44	0.34
FLT4	rs307826 A>G	T494A	74	53	19	2	0.16	0.10
HIF1A	rs11549465 C>T	P582S	72	53	17	2	0.15	0.07
IL1b	rs1143634 C>T	F105F	73	39	31	3	0.25	0.21
IL4	rs2243250 C>T	Promoter	75	56	18	1	0.13	0.14
IL8	C>1 rs4073 T>A	5'near gene	72	24	36	12	0.42	0.40
IL10	rs1800896 A > G	5´near gene	74	23	40	11	0.42	0.47
IL10	rs1800872 C > A	5´near gene	73	36	29	8	0.31	0.21
KDR	rs2305948 C>T	V297L	75	65	10	0	0.07	0.08
KDR	rs1870377 T > A	Q472H	74	43	28	3	0.23	0.27
KDR	rs2071559 C>T	5′near gene	74	22	30	22	0.50	0.49
KDR	rs7692791 T > C	Intron	74	18	41	15	0.48	0.48
KDR	rs1531289 C>T	Intron	74	32	34	8	0.34	0.29
MTOR	rs11121704 T > C	Intron	74	37	33	4	0.28	0.27
MTOR	rs2295080 T > G	3'near gene	74	31	34	9	0.35	0.30
MTOR	rs1074078 C>T	5´near gene	75	28	35	12	0.39	0.32
NOS3	rs1799983 G>T	D298E	72	22	37	13	0.44	0.34
PDGFRA	rs35597368 T>C	S478P	73	55	16	2	0.14	0.13
PDGFRA	rs1800813 G>A	5'near gene	74	46	25	3	0.21	0.21
PDGFRA	rs1800810 C>G	Promoter	73	45	24	4	0.22	0.21
PDGFRA	rs1800812 G>T	Promoter	74	43	25	6	0.25	0.21
PGF	G > 1 rs8185 A > G	3'-UTR	74	52	20	2	0.16	0.17
PIK3CA	rs7651265	Intron	74	56	17	1	0.13	0.12
	A > G							

Gene	SNP	Variation	Patients*	Homozygous wild-type	Heterozygous	Homozygous variant	Observed MAF	MAF in dbSNP
PIK3CA	rs7640662 C > G	Intron	75	54	19	2	0.15	0.14
PIK3CA	rs7621329 C>T	Intron	75	40	29	6	0.27	0.12
PIK3CA	rs6443624 C>A	Intron	75	36	29	10	0.33	0.17
PIK3CA	rs2699887 G > A	Intron	75	42	31	2	0.23	0.26
PTEN	rs2299939 C>A	Intron	75	55	17	3	0.15	0.20
PTEN	rs12569998 T > G	Intron	74	59	14	1	0.11	0.14
PTEN	rs12357281 G>C	Intron	75	66	9	0	0.06	0.06
PTGS2	rs5275 T > C	3'-UTR	74	40	27	7	0.28	0.38
RET	rs1799939 G > A	G691S	73	48	21	4	0.20	0.11
RHEB	rs717775 A > C	Intron	74	34	33	7	0.32	0.28
RICTOR	rs2043112 C>T	S837F	75	26	35	14	0.42	0.41
RPTOR	rs7211818 A>G	Intron	75	46	25	4	0.22	0.24
RPTOR	rs11653499 A>G	Intron	74	40	23	11	0.30	0.30
RPTOR	rs7212142 G > A	Intron	75	20	42	13	0.45	0.38
RPTOR	rs9674559 A > G	Intron	74	45	25	4	0.22	0.25
TGFB1	rs1800469 C>T	5´near gene	66	26	33	7	0.36	0.29
TGFBR1	rs868 A > G	3'-UTR	74	46	24	4	0.22	0.20
TNF	rs1800629 G > A	Intron	73	62	10	1	0.08	0.17
TNF	rs361525 G > A	5´near gene	74	63	1	10	0.14	0.07
TNF	rs1799724 C>T	5´near gene	74	61	13	0	0.09	0.07
TSC2	rs2073636 C>T	Intron	74	29	35	10	0.37	0.44
TSC2	rs8063461 G > A	Intron	75	28	39	8	0.37	0.44
VEGFA	rs2010963 G>C	5'-UTR	75	32	35	8	0.34	0.20
VEGFA	rs1570360 G > A	5'near gene	74	42	25	7	0.26	0.28
VEGFA	rs699947 C>A	5'near gene	75	26	35	14	0.42	0.48
VEGFA	rs3025039 C>T	3'-UTR	74	54	18	2	0.15	0.18
VEGFA	rs25648 C>T	\$178S	74	54	17	3	0.16	0.18
VEGFA	rs2146323 C>A	Intron	74	37	30	7	0.30	0.34

 Table 2. Polymorphisms genotyped and allele frequency. Abbreviations: dbSNP, SNP database (http://www.ncbi.nlm.nih.gov/snp/); MAF, minor allele frequency; rs, reference SNP; SNP, single nucleotide polymorphism; UTR, untranslated region. *Patients successfully genotyped.

is associated with more than five-fold increased risk of cancer-related death. This finding is consistent with the observed effect in early breast cancer and in advanced colorectal cancer where rs5275 was correlated with distant disease-free survival²⁰ and, with progression-free and overall survival, respectively²¹. It is noteworthy that rs5275 improves the potential risk prediction found in other different genetic markers in similar series of mRCC treated with sunitinib²².

The genetic variant rs5275 is located in the 3'UTR of the *PTGS2* gene that encodes the protein COX2. It has been described that C allele disrupts miR-542–3p binding, allowing for mRNA stabilization and leading to a significant increase in both COX2 mRNA and protein levels in colorectal cancer¹⁸. Our results confirm the association of C allele in mRCC patients with higher mRNA expression levels, thereby expecting an increase in protein

			Progression-free survival			Cancer-specific		
Gene	SNP	Inheritance model	P (Univariate)	P (Multivariate)	HR (95% CI)	P (Univariate)	P (Multivariate)	HR (95% CI)
AKT1	rs3803304	Additive	0.039	0.076	0.66 (0.42-1.06)	0.103	_	
AKT1	rs2494738	Dominant	0.530	—		0.058	0.078	2.73 (0.94-7.96)
FLT4	rs307826	Additive	0.038	0.038	1.42 (1.03–1.95)	0.863	_	
IL4	rs2243250	Dominant	0.224	—		0.016	0.0009*	4.69 (1.92–11.44)
KDR	rs1870377	Dominant	0.762	—		0.085	0.388	0.66 (0.26–1.70)
MTOR	rs2295080	Additive	0.049	0.280	0.84 (0.62–1.15)	0.098	0.405	0.81 (0.50-1.33)
PGF	rs8185	Dominant	0.395	—		0.068	0.129	1.99 (0.84-4.74)
PIK3CA	rs7651265	Dominant	0.031	0.025	0.43 (0.19-0.96)	0.139	_	
PIK3CA	rs7640662	Dominant	0.084	0.120	1.64 (0.90-3.00)	0.304	—	
PTGS2	rs5275	Recessive	0.004	0.053	3.03 (1.10-8.33)	0.005	0.010*	5.22 (1.70-15.98)
RET	rs1799939	Additive	0.037	0.150	0.79 (0.56-1.10)	0.078	0.284	0.74 (0.42–1.30)
RICTOR	rs2043112	Recessive	0.097	0.140	1.77 (0.79–3.97)	0.059	0.058	3.40 (0.78-14.95)
TNF	rs361525	Additive	0.911	—		0.08	0.820	0.87 (0.26-2.88)
VEGFA	rs699947	Dominant	0.109	—		0.046	0.148	0.50 (0.20-1.27)
VEGFA	rs25648	Dominant	0.189	_		0.015	0.159	0.43 (0.12–1.53)

Table 3. Univariate and multivariate analyses of polymorphisms associated with progression-free survival and cancer-specific survival in patients with metastatic renal cell carcinoma treated with sunitinib. Abbreviations: CI, confidence interval; HR, hazard ratio; rs, reference SNP; SNP, single nucleotide polymorphism Multivariate analysis includes MSKCC risk groups and prior nephrectomy as covariates for progression-free survival and, histology, MSKCC risk groups and prior nephrectomy for cancer-specific survival. **P* value remained significant after adjustment for multiplicity using Benjamini-Hochberg method.

.....

level. This presumption is supported by the correlation of high COX2 protein levels with shorter progression-free and cancer-specific survival in clear cell RCC^{23} and it is in agreement with the known role of COX2 in cancer²⁴.

In order to evaluate the cumulative effect of the most relevant SNPs, different combinations have been tested. For PFS, a combination of rs5275 (*PTGS2*) and rs7651265 (*PIK3CA*) resulted in a promising marker for determining risk of progression after sunitinib treatment. A difference of 24 months in survival between high and low risk groups of patients was observed and remained significant after the Benjamini-Hochberg correction for multiple comparisons (Table 4). So far, rs7651265 (*PIK3CA*) has been only associated with susceptibility to ovarian and colon cancer^{25,26}. Therefore, this is the first association with cancer patient outcome. The role of this biomarker in mRCC is supported by the recent study performed by the Cancer Genome Atlas Research Network confirming the PI3/AKT pathway as one of the most relevant pathways in RCC²⁷.

In the case of CSS, the combination of the deleterious genotypes for rs5275 (*PTGS2*) and rs2243250 (*IL4*) showed more than 7 times higher death risk compared to the patients with none of deleterious genotypes. This model provided a better predictive capacity than each SNP individually (Supplementary Table S3).

Interestingly, the two-SNPs models associated with PFS and CSS harboured the variant rs5275 in *PTGS2* supporting for the first time the relevance of this functional genetic variant as predictive marker in mRCC.

One of the proposed mechanisms of resistance to anti-angiogenic therapy is that in the presence of agents targeting the VEGF pathway, alternative pro-angiogenic pathways are activated. The identification of predictive genetic markers in *PTGS2*, *IL4* and *PIK3CA* highlights, for the first time, the relevance of tumour microenvironment, inflammatory response and PI3K/AKT pathway activation in sunitinib treatment resistance. The functionality of the variants in *IL4* and *PTGS2* which leads to increased mRNA levels and thereby to higher expression of IL-4 and COX2 is associated with a lower potential clinical benefit of sunitinib.

The strength of these proposed predictors is that they are detected in the germline DNA, which is inherited, and insensitive to time and environmental factors. Since no reliable cancer predictive biomarker for sunitinib response has been implemented in the clinic yet, validation of our findings in an independent series of mRCC patients is warranted before put these markers into practice.

Our study had limitations. Schedule and dose modifications were not dictated by central protocol, and timing for radiological assessments was done according to each institution's policy. Thus, courses of treatment were not standardized for the study and outcomes were assessed with regard to present practice. Finally, our study did not include a prospective, external validation. Because our patients were Caucasian, the relevance of these polymorphisms needs to be assessed in other ethnic groups. On the other hand, the SNPs that we found to be associated with sunitinib outcome are relatively common (13% for rs7651265, 13% for rs2243250, 16% for rs307826, and 28% for rs5275) and in addition, two of them (rs2243250 and rs5275) has been proven to be functional, which increases the power of the study. These factors are probably the major contributors to the robustness of our results, with statistically significant outcomes that persisted after adjustment for multiple testing. Our results warrant pharmacokinetic studies to better understand the molecular mechanisms and further validation in independent series.

The use of these genetic variants as novel predictive markers of response to sunitinib could provide a clinically relevant tool to improve mRCC patient management. In this way, if patients with a specific genotype are unlikely to benefit from sunitinib, an alternative therapy should then be used.






Figure 1. Association of single nucleotide polymorphism rs2243250 (IL4) (A) and rs5275 (PTGS2) (B) with cancer-specific survival in metastatic renal cell carcinoma patients treated with sunitinib. Correlation between PTGS2 mRNA expression levels according to rs5275 genotypes (C). Gene expression was determined in patients carrying T allele (TT/TC) or homozygous for C allele. There is a significant difference between the T carriers and CC genotype (P = 0.013).

Methods


Patients. This is a multicenter, prospective and observational study in which patients with any subtype of mRCC and receiving any standard treatment were recruited. Twenty different hospitals enrolled patients between April 29, 2009, and July 15, 2010, and closed the follow-up database in March 20, 2012. This study was approved by the Institutional Ethical Committee at the Navarra Regional Government (authorization number 3066K1 4433) and the methods were carried out in accordance with the approved guidelines and regulations. All patients signed written informed consent before recruitment. Only patients treated with sunitinib as monotherapy in first line were analyzed since it was the most homogeneous subgroup. Drug treatment schedule and dose-reduction policy were decided by the attending doctors, in accordance with the current local practice guidelines and regulations. The inclusion criteria comprised patients that should be at least 18 years of age, with a verifiable diagnosis of mRCC. Patients who had been previously treated with any other medical therapy for RCC, and/or with history of other cancer disease apart RCC were excluded, except for those who had received curative treatment and were cancer-free in the last 5 years. Following the above mentioned criteria, eighty-two patients were assessed for eligibility.

According to the most widely used prognostic factor model from Memorial Sloan-Kettering Cancer Center (MSKCC)²⁸, patients were categorized into favourable, intermediate and poor prognosis groups. The MSKCC score is based on 5 risk factors: low Karnofsky performance status (<70%), high lactate dehydrogenase levels (>1.5 times the upper limit of normal), low serum hemoglobin level, high corrected serum calcium concentration (>10 mg/dL), and time from initial diagnosis to treatment < 1 year.

Genetic polymorphisms and genotyping. Genomic DNA was isolated from peripheral blood using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany), according to the manufacturer. Seven patients were excluded because of low DNA quality or poor DNA vield.

A total of 63 SNPs in 31 different genes were selected. The chosen SNPs were located in genes affecting sunitinib pharmacodynamics: PDGF- and VEGF-dependent angiogenesis (ARNT, HIF1A, FLT4, KDR, PDGFRA, PGF and VEGFA) or pro-angiogenic pathways (CXCL12, FGFR2, FGFR4 and IL8). Also were selected those genes encoding other sunitinib targets (FLT3, RET), involved in the PI3K/AKT pathway (AKT1, AKT2, AKT3, PIK3CA, PTEN, NOS3), or in the mTOR pathway (MTOR, RHEB, RPTOR, RICTOR, TSC2) and, a set of genes encoding cytokines and inflammatory mediators (IL1B, IL4, IL10, PTGS2, TGFB1, TGFBR1 and TNF).

The SNP genotyping was performed using Tagman products (Applied Biosystems, Foster City, CA, USA). The PCR was performed on the 7500 Real-Time PCR System (Applied Biosystems).






Figure 2. Kaplan-Meier curves for each of the proposed two-SNPs models. (**A**) Progression-free survival for patients grouped by adverse genotypes in rs5275 (*PTGS2*) and rs7651265 (*PIK3CA*). (**B**) Cancer-specific survival for patients stratified according to combination of deleterious genotypes in rs5275 (*PTGS2*) and rs2243250 (*IL4*).

	Progression-free survival			
	HR (95% CI)	P (Univariate)	HR (95% CI)	P* (Multivariate)
PTGS2 & PIK3CA				
rs5275 or rs7651265 vs. none	2.45 (1.10-5.44)	0.029	2.84 (1.18-6.80)	0.020
rs5275 & rs7651265 vs. none	7.83 (2.43–25.19)	0.001	5.44 (1.39-21.32)	0.015
	Cancer-specific survival			
	HR (95% CI)	P (Univariate)	HR (95% CI)	P* (Multivariate)
PTGS2 & IL4				
rs5275 or rs2243250 vs. none	2.10 (0.88-5.02)	0.094	4.02 (1.52-10.63)	0.005
rs5275 & rs2243250 vs. none	5.89 (2.09-16.58)	0.001	7.32 (2.10-25.54)	0.002

Table 4. Univariate and multivariate analyses of two-SNPs combination models associated with progression-free survival and cancer-specific survival in patients with metastatic renal cell carcinoma treated with sunitinib. Abbreviations: CI, confidence interval; HR, hazard ratio; rs, reference SNP Multivariate analysis includes MSKCC risk groups and prior nephrectomy as covariates for progression-free survival and, histology, MSKCC risk groups and prior nephrectomy for cancer-specific survival. **P* value remained significant after adjustment for multiplicity using Benjamini-Hochberg method.

PTGS2 mRNA expression analysis. Total RNA was isolated from peripheral blood using the PAXgene Blood RNA Isolation System (PreAnalytiX GmbH, Switzerland). cDNA was synthesized using High Capacity cDNA Archive Kit (Applied Biosystems).

PTGS2 gene expression was analyzed using 7500 Fast Real-Time PCR System (Applied Biosystems) and normalized to *PSMB4* expression. The probes used were Hs00153133_m1 for *PTGS2* and Hs00160598_m1 for *PSMB4*.

Statistical analysis. Progression-free survival (PFS) was defined as the time between the first day of sunitinib and the date of progressive disease (PD) according to Response Evaluation Criteria in Solid Tumours (RECIST), clear clinical evidence of PD or death due to PD, or was censored at last follow-up. Cancer-specific

survival (CSS) was defined as the time from the first day of sunitinib treatment and the date of death from cancer or was censored at the date of last follow-up.

Cox regression analysis was used to correlate each SNP with PFS and CSS. All genetics and clinical variables with a P < 0.1 were selected as candidate for multivariate Cox regression analysis. Survival curves were determined by the Kaplan-Meier method, with log-rank tests assessing the differences between the groups.

Predictive two-SNPs models for PFS or CSS were developed combining significant variants in the multivariate analyses. The predictive ability of the models was assessed using the area under the receiver operating characteristic (ROC) curve (AUC).

All individual and combined SNPs that were significant after multivariate analysis were corrected for multiple comparisons using Benjamini-Hochberg false discovery rate test. Statistical analyses were done using SPSS v20 software and R 3.1.0. *P* values \leq 0.05 were considered statistically significant.

References

- 1. Gupta, K., Miller, J. D., Li, J. Z., Russell, M. W. & Charbonneau, C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. *Cancer Treat Rev* 34, 193–205 (2008).
- 2. Motzer, R. J. et al. Kidney cancer. J Natl Compr Canc Netw 9, 960–977 (2011).
- 3. Chow, L. Q. & Eckhardt, S. G. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25, 884–896 (2007).
- 4. Motzer, R. J. *et al.* Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. *J Clin Oncol* 27, 3584–3590 (2009).
- Makhov, P. B. et al. Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells. Mol Cancer Ther 11, 1510–1517 (2012).
- 6. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
- Fox, P. *et al.* Markers of systemic inflammation predict survival in patients with advanced renal cell cancer. *Br J Cancer* 109, 147–153 (2013).
 Heng, D. Y. *et al.* Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. *J Clin Oncol* 27, 5794–5799 (2009).
- 9. Kim, H. D. *et al.* Interleukin-4 induces senescence in human renal carcinoma cell lines through STAT6 and p38 MAPK. *J Biol Chem* 288, 28743–28754 (2013).
- Daurkin, I. et al. Tumor-associated macrophages mediate immunosuppression in the renal cancer microenvironment by activating the 15-lipoxygenase-2 pathway. Cancer Res 71, 6400–6409 (2011).
- 11. Mitropoulos, D. *et al.* Expression of transforming growth factor beta in renal cell carcinoma and matched non-involved renal tissue. *Urol Res* **32**, 317–322 (2004).
- Chen, Q., Shinohara, N., Abe, T., Harabayashi, T. & Nonomura, K. Impact of cyclooxygenase-2 gene expression on tumor invasiveness in a human renal cell carcinoma cell line. J Urol 172, 2153–2157 (2004).
- 13. Hashimoto, Y. *et al.* Cyclooxygenase-2 expression and relationship to tumour progression in human renal cell carcinoma. *Histopathology* **44**, 353–359 (2004).
- 14. Miyata, Y. *et al.* Expression of cyclooxygenase-2 in renal cell carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival. *Clin Cancer Res* **9**, 1741–1749 (2003).
- Rosenwasser, L. J. et al. Promoter polymorphisms in the chromosome 5 gene cluster in asthma and atopy. Clin Exp Allergy 25 Suppl 2, 74-78; discussion 95–76 (1995).
- 16. Nakashima, H. et al. Association between IL-4 genotype and IL-4 production in the Japanese population. Genes Immun 3, 107–109 (2002).
- Kleinrath, T., Gassner, C., Lackner, P., Thurnher, M. & Ramoner, R. Interleukin-4 promoter polymorphisms: a genetic prognostic factor for survival in metastatic renal cell carcinoma. J Clin Oncol 25, 845–851 (2007).
- Moore, A. E., Young, L. E. & Dixon, D. A. A common single-nucleotide polymorphism in cyclooxygenase-2 disrupts microRNAmediated regulation. *Oncogene* 31, 1592–1598 (2012).
- 19. Li, Z. et al. Endogenous interleukin-4 promotes tumor development by increasing tumor cell resistance to apoptosis. Cancer Res 68, 8687–8694 (2008).
- Jung, J. H. et al. TNF superfamily gene polymorphism as prognostic factor in early breast cancer. J Cancer Res Clin Oncol 136, 685–694 (2010).
- Kim, J. G. et al. Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T > C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin. Cancer Chemother Pharmacol 64, 953–960 (2009).
- Garcia-Donas, J., Rodriguez-Moreno, J. F., Romero-Laorden, N. & Rodriguez-Antona, C. Renal carcinoma pharmacogenomics and predictors of response: Steps toward treatment individualization. Urol Oncol 33, 179–186 (2014).
- Lee, J. W. et al. Cyclooxygenase-2 expression and its prognostic significance in clear cell renal cell carcinoma. Korean J Pathol 46, 237–245 (2012).
- 24. Rizzo, M. T. Cyclooxygenase-2 in oncogenesis. Clin Chim Acta 412, 671-687 (2011).
- 25. Quaye, L. et al. Tagging single-nucleotide polymorphisms in candidate oncogenes and susceptibility to ovarian cancer. Br J Cancer 100, 993–1001 (2009).
- Slattery, M. L. *et al.* Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1. *Carcinogenesis* 31, 1604–1611 (2010).
- 27. Cancer Genome Atlas Research Network: Comprehensive molecular characterization of clear cell renal cell carcinoma. *Nature* **499**, 43–49 (2013).
- Motzer, R. J. et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 20, 2376–2381 (2002).

Acknowledgements

Supported by Pfizer.

Author Contributions

YM., AV and JG.-F conceived and designed the research study. MR-R and VB developed the methodology. MJM-V, MLG, NL, DC, IG-C, EE, MIS, RV, CS, AC, J.M-F, LB, MG-A, JLG-L, BP-V, JC-J, AG-A, FM, GR and JG-F collected the clinical samples. AC, TG-P and IM-F analyzed and interpreted the data. AC, TG-P, MJM-V, MLG, NL, DC, IG-C, EE, MIS, RV, CS, AC, JM-F, LB, MG-A, JLG-L, BP-V, JC-J, AG-A, FM, GR, AV, JG-F contributed to preparing and reviewing the manuscript. AC, TG-P, YM., AV gave administrative, technical, or material support. AV, JG-F supervised the study.

Additional Information

Supplementary information accompanies this paper at http://www.nature.com/srep

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Cebrián, A. *et al.* Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib. *Sci. Rep.* **7**, 41371; doi: 10.1038/ srep41371 (2017).

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2017